How could metabolomics contribute to COVID-19 research?

Sars-CoV-2 is a novel coronavirus. Thus, the biology is not well characterized yet. Among the issues that we need to understand better are the factors that contribute to the heterogenic outcomes of Covid-19, and the reasons that put elderly populations at increased risk of severe disease courses. Against this backdrop, biomarkers that can be predictive of probable disease progression or the response to a specific course of therapy would be highly valuable to personalize treatments at every stage of the disease.

As the metabolome is highly dynamic and changes in metabolism often precede changes in the clinical phenotype, metabolomics could play an important role in shaping our understanding of this infection. At Biocrates, we are confident that quantitative, standardized and targeted metabolomics solutions are the ideal tools to tackle this challenge.

Successful examples for biomarker research in sepsis, pneumonia and co-morbidities associated with many Covid-19 infections provide evidence of the potential of metabolomics to bring about personalized health care for Covid-19 patients, providing safe and effective treatments to patients. 

Metabolic pathways relevant for patient stratification and response testing

• Immunity related amino acids and related metabolites (e.g. tryptophan and related metabolites)

• Steroid hormones and other immunomodulatory metabolites containing a cholesterol backbone (e.g. bile acids)

• Lipid inflammatory mediators (e.g. ceramides)

• Metabolites related to mitochondrial function/energy homeostasis (e.g. acylcarnitines)

• Metabolites related to Mode of Action of study drug and/or drug toxicity

What do you think?

Can metabolomics help treating COVID-19 patients more efficiently and alleviate the burdons on hospitals?

0 Comments

Submit a Comment

Your email address will not be published.

Relevant Literature

• Prognosis of disease severity and adverse outcome/survival in community-acquired pneumonia and COPD patients
Meier et al., Lung 2017

• Mortality prediction in patients with sepsis and septic shock
Ferrario et al., Sci Rep 2016; Recknagel et al., PLoS Med. 2012

• Diagnostic and prognostic markers in patients with heart failure
Cheng et al., J. Am. Coll. Cardiol. 2015

• Therapy response in early septic shock patients
Cambiaghi et al., Sci Rep 2017

• Very long-chain fatty acid-containing lipids as potential biofuels for successful immune checkpoint inhibition
Mock et al., Cancer Immunol Immunother. 2019

For Research Use Only. Not for use in diagnostic procedures.